Reasonable application of antilipemic agents in patients with kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2014.05.003

Abstract

Abstract:

Currently, the morbidity of hyperlipemia in our country has increased year by year. And data showed that the prevalence of dyslipidemia has been as high as 18.2%, which has become an important public health problem of residents in our country. Clinical studies have confirmed that dyslipidemia is closely related to chronic kidney disease (CKD). They cause, affect, and promote each other. Ideal lipid level helps to improve the long-term prognosis of patients with CKD. CKD patients with dyslipidemia, first of all,should adjust the life style and had their primary diseases treated actively. What is important is to reasonably select antilipemic agents according to the different types of dyslipidemia, in order to achieve the target value and delay the progression of CKD course.

Key words: Chronic kidney disease, Dyslipidemia, Treatment

Ying Li. Reasonable application of antilipemic agents in patients with kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(05): 236-240.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.05.003

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I05/236

References 22

1	Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in chinese adults [J].Circulation,2006,114(21):2217-2225.
2	EuropeanAssociationforCardiovascularPrevention&Rehabilitation, Reiner Z,Catapano AL,et al. ESC/EAS Guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology(ESC) and the European Atherosclerosis Society( EAS) [J]. Eur Heart J,2011,32(14):1769-1818.
3	Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition [J]. JAMA,2004,291 (4):451-459.
4	D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study [J]. Circulation,2008,117(6):743-753.
5	Muntner P,He J,Astor BC,et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease:results from the atherosclerosis risk in communities study [J]. J Am Soc Nephrol,2005,16(2):529-538.
6	Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction [J]. J Am Coll Cardiol, 2005, 46(7):1225-1228.
7	NKF-K/DOQI 慢性肾脏病血脂异常管理的临床实践指南[J].中国血液净化,2007,6(12):672-681.
8	Sharp Collaborative Group. Study of Heart and Renal Protection(SHARP): randomized trial to assess the effects of lowering lowdensity lipoprotein cholesterol among 9,438 patients with chronic kidney disease[J]. Am Heart J,2010,160(5):785-794.
9	Alcala A, Jansen S, Tellez T, et al. Statins improve visual field alterations related to hypercholesterolemia [ J]. Athrosclerosis,2010,269(2):512-514.
10	Fried LF, Orchard TJ, Kasiske BL. The effect of lipid reduction on renal disease progression: a meta-analysis. Kidney Int, 2001, 59(1):260-269.
11	Sabrina S, Natasha W, Linda FF, et al. Statins for improving renal outcomes: a meta-analysis [J]. J Am Soc Nephrol,2006,17(7):2006-2016.
12	Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C,Blackwell L, et al.Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials[J].Lancet,2010,376(9753):1670-1681.
13	Olsson B, Gigante B,Mehlig K, et al. Apolipoprotein C-1 genotype and serum levels of triglycerides, C-reactive protein and coronary heart disease [J]. Metabolism,2010,19(12):1736-1741.
14	National Kidney Foundation. KDOQITM Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J]. Am J Kidney Dis, 2007, 49(Suppl 2): S1-S180.
15	郭丹杰, 徐成斌. 贝特类调脂药物在降脂领域的地位及认识[J].临床药物治疗杂志,2008,6(2):1-3.
16	Aim-High Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med, 2011,365(24):2255-2267.
17	Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of highdensity lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data metaanalysis of 23 studies in the asia-pacific region [J]. Circulation,2011,124(19):2056-2064.
18	Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholester-ol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial[J]. Lancet, 2011, 377 (9784): 2181-2192.
19	Siscovick DS, Lemaitre RN, Mozaffarian D. The fish story: a dietheart hypothesis with clinical implications: N-3 polyunsaturated fatty acids,myocardial vulnerability,and sudden death [J]. Circulation,2003,107(21):2632-2634.
20	Ozsoy RC, Kastelein JJ, AriszL, et al. A torvas tat in and the dys lip -idem ia of early renal failure [J]. Atherosclerosis, 2003, 166(1) :187-194.
21	ACCORD Study Group.Effects of combination lipid therapy in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1563-1574.
22	Baigent C,Landry M. Study of heart and renal protection (SHARP)[J]. Kidney Int,2003,63(Suppl 84): S207-S210.

[1]	Baicheng Yi, Xuguang Li, Rongrong Wang, Xinxuan Wang. Treatment of calcified root canals in upper anterior teeth using digital 3D-printing guides：A clinical report of two cases [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2024, 18(06): 385-390.
[2]	Huayue Yan, Zixiang Liu, Shaobo Zhou. Research progress of phosphoenolpyruvate carboxykinase-1 in malignant tumors [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 452-456.
[3]	Huazhi Li, Guang Cao, Diangang Liu, Yajing Zhang. Clinical comparison of descending hepatectomy with different approaches for primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 52-55.
[4]	Hao Chen, Meng Wang. Advances in clinicopathological features and treatment options of sig-ring cell carcinoma of the stomach [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 108-111.
[5]	Yuefang Xu, Wang Liu, Miaotian Zeng, Yushu Guo. Clinical efficacy of polymyxin B and polymyxin E in the treatment of surgical multi-drug resistant infections Security analysis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 700-703.
[6]	of Organ Transplantation of Chinese Medical Association Branch. Chinese practice guidelines for diagnosis and treatment of ischemic-type biliary lesion after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 739-748.
[7]	Qiusheng Wang. Diagnosis and treatment strategy for benign biliary diseases [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 779-782.
[8]	Yifan Li, Diwen Zhu, Weixin Ren, Yingjun Bao, Junpeng Gu, Haixiao Zhang, Gengfei Cao, Weizheng Ji. Role of serum GP73 level in the evaluation of TACE efficacy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 825-830.
[9]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[10]	Xuefeng Zhou, Zheyi Dong, Zhe Feng, Guangyan Cai, Xiangmei Chen. Formulation protocol of guidelines for diagnosis and treatment of diabetic kidney disease with integrated traditional Chinese and Western medicine [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 301-305.
[11]	Bin Shi, Yuan Si. Effect of Yiqiheluo formula combined with valsartan in the treatment of IgA nephropathy with deficiency of both qi and yin plus blood stasis syndrome [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 306-312.
[12]	Wenkai Guo, Pengcheng Ji, Jingru Bi, Yuansheng Xie. Ten treatment measures for IgA nephropathy [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 327-333.
[13]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[14]	Xuan Tie, Xiaole Su, Lihua Wang. Progress of research on the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 345-351.
[15]	Tianyu Wu, Zixuan Liu, Puxin Yang, Siming Jia, Kai Ding, Xiaodong Cheng, Yonglong Li, Wei Chen, Hongzhi Lyu, Qi Zhang. Progress in Conservative Treatment of Lumbar Disc Herniation [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 379-384.

Please choose a citation manager

Content to export